**Core tip:** The phosphatidylinositol 3-kinase-mammalian target of rapamycin (PI3K-mTOR) pathway sustains cancer progression and drug resistance. The first Food and Drug Administration approved molecule against this pathway was everolimus, an mTOR inhibitor, to be used in combination with exemestane in hormone receptor positive/human epidermal growth factor receptor 2 negative breast cancers progressing to non-steroidal aromatase inhibitors. Drugs targeting other effectors such as PI3K, PI3Kα, Akt and mTORC1/2 have gained clinical interest. Nevertheless, everolimus remains the best option due to the relevant toxicity of the other drugs targeting the PI3K-mTOR pathway. Future directions point towards the development of biomarkers that would identify those patients who would benefit from the PI3K-mTOR inhibitors for improving overall survival.

INTRODUCTION
============

With the introduction of molecular technologies, breast cancer (BC) has been divided into four main subtypes: luminal A, luminal B, human epidermal growth factor receptor 2 (HER2), or triple negative. The luminal variants, due to the hormone receptor positive (HR+) expression, have a generally favourable prognosis in the non-metastatic setting. Some of the most commonly used drugs for the treatment of HR+ disease have been anti-oestrogen therapies, *e.g*. tamoxifen and aromatase inhibitors (AI) - such as anastrozole or letrozole or exemestane. In BC survivors, metastatic breast cancer (MBC) is a treatable but still incurable disease. The majority of HR+ MBCs develop resistance to anti-oestrogen treatments\[[@B1],[@B2]\]. Cancer driver mutations and/or constitutive activation in the key signalling pathway genes of phosphatidylinositol 3-kinase-mammalian target of rapamycin (PI3K-mTOR) cascade are capable of overriding anti-oestrogen treatments in BC cells\[[@B3]\]. In particular, *PIK3CA* is mutated in 20%-40% of BC\[[@B4],[@B5]\], representing therefore an interesting target for therapies. For these reasons, inhibitors of the PI3K-mTOR pathway was pursued in clinical development until one of them, an mTOR inhibitor-a derivative of rapamycin - named everolimus, reached Food and Drug Administration (FDA) approval for the treatment of the disease in 2012, in combination with exemestane, for second line treatment of HR+/HER2- BCs that have previously regressed to anastrozole or letrozole treatment.

This commentary is focused on the outcomes coming from the most important clinical trials, testing everolimus in combination with other drugs: TAMRAD (Tamoxifen Plus Everolimus), BOLERO-2 (OraL EveROlimus-2), BOLERO-4, BOLERO-6, BELLE-2 and BELLE-3. Future directions and perspectives testing therapeutical combinations targeting different effectors are also discussed.

PI3K-mTOR PATHWAY
=================

PI3K-mTOR signaling events play an important role in the modulation of cell survival, proliferation, motility and apoptosis: activation of PI3K phosphorylates Akt, shifting thereby the protein in the activated form that localizes in the plasma membrane. Subsequently a cascade of downstream events are activated, including the inhibition of p27 and the increase of the transcription factor CREB levels and, consequently, of the cell cycle promoter cyclin A, leading to mTOR activation that promotes the expression of genes related to cell proliferation. The aberrant activation of the PI3K-mTOR pathway sustains cancer cell survival and proliferation and also contributes to anti-oestrogen treatment resistance.

*PIK3CA* mutations constitutively activate the PI3K signal transduction pathway, which ultimately leads to the phosphorylation of PIP~2~ into PIP~3,~ thus activating the phosphatidylinositol signalling bringing to higher cell survival and to inhibition of apoptosis. Predominantly mutations of *PI3KCA* occur around hotspots E542/5 (exon 9) and H1047 (exon 20) at the catalytic subunit\[[@B6]-[@B9]\]. Additionally, *AKT* or *PTEN* mutations overrides anti-oestrogen therapies\[[@B4],[@B10]\]. Eventually, PIP~3~ phosphorylates Akt (pAkt is the active form), which then activates the mTOR.

Of note, PI3K activation has been shown to cause a decrease in ER levels and therefore a lesser degree of response to anti-oestrogen therapies\[[@B11]\]. Targeting PI3K could be capable of restoring ER sensitivity\[[@B12]\]. Therefore, PI3K-mTOR pathway inhibition plus endocrine therapies represent an interesting strategy to pursue. There is a link between ER and mTORC1: mTORC1 can phosphorylate ER at S167 through p70S6K or it can also phosphorylate ER at S104/S106, thus resulting in ER activation\[[@B13]\]. Of note, recently, Sonnenblick et al\[[@B14]\] discovered a gene signature related to the phosphorylation of Akt (pAkt) and mTOR (p-mTOR) in early ER+ BC. Analyzing gene expression and proteomic data collected from over 7000 early BC, they found pAkt correlated to luminal A and a good prognosis, whereas p-mTOR was found in worse prognosis luminal B cases. Interestingly, the signatures of pAkt and p-mTOR correlated to *PI3KCA* mutations positively and negatively, respectively. The authors underlined the different role at the molecular level of pAkt and p-mTOR effectors in early luminal BC, a matter that further contributes to the heterogeneity of the disease\[[@B14]\].

CLINICAL TRIALS
===============

The discovery of everolimus led to the hypothesis of synergism in co-targeting two different pathways in HR+/HER2- advanced BC patients: the mTOR and the HRs pathways. Such hypothesis has been tested in several clinical trials.

The TAMRAD trial was a phase 2, randomized clinical trial that tested the combination of everolimus with tamoxifen in postmenopausal women with MBC and resistance to AI. Besides proving to be a safe approach, it demonstrated that the combination of these treatments was capable of increasing the clinical benefit rate (CBR) from 42% with tamoxifen to 61% with the combination. The time to progression increased from 4.5 mo in patients receiving only tamoxifen to 8.6 mo in patients receiving both tamoxifen and everolimus. The death risk was reduced by 55% after treating patients with tamoxifen plus everolimus in comparison to tamoxifen alone\[[@B15]\]. Interestingly, the combination was efficient in patients who responded to AIs but subsequently became resistant to AIs. Contrarily, the combination was not effective in *de novo* treated MBC HR+\[[@B16]\].

The BOLERO-2 trial was a phase 3, randomized, double-blinded, multicentre clinical trial that recruited 724 HR+ MBC patients. This trial evaluated everolimus with the steroideal AI as exemestane compared to exemestane and placebo. Patients who were enrolled in this clinical trial had previously received AI anastrozole or letrozole. This clinical trial showed an improved progression free survival (PFS) of 11 mo in the exemestane + everolimus arm compared to the 4.1 mo placebo + exemestane ones \[*P* \< 0.0001; hazard ratio = 0.38; 95% confidence interval (CI): 0.31-0.48\]\[[@B17]\]. This shows that the combination of everolimus with exemestane doubled up the PFS time versus placebo plus exemestane alone; these results led to the FDA approval of everolimus with exemestane in the treatment of HR+ MBC patients who did not respond to letrozole nor anastrozole treatments.

Recent studies further tested everolimus in combination with other therapies as first line in HR+ BC patients. The BOLERO-4 (NCT01698918) and BOLERO-6 (NCT01783444) tested everolimus with different combinations of drugs. BOLERO-4 was a single arm, open labeled phase 2 study evaluating in 202 ER+, HER2- advanced BC patients the PFS of first line everolimus + letrozole and in a quarter of them whose disease progressed, everolimus + exemestane as second line. This study demonstrated the efficacy of everolimus + letrozole with a median PFS of 22 mo, whereas the second line everolimus + exemestane, which was used in some of the progressed patients, gave limited results with a median PFS of only 3.7 mo\[[@B18]\]. The BOLERO-6 was a randomized open-labeled study, comparing second line therapies everolimus + exemestane against everolimus or capecitabine alone in 309 AI-resistant ER+, HER2- MBC patients. Consistent with the BOLERO-2 study, robust evidence of superiority in median PFS was registered for everolimus + exemestane versus everolimus alone but surprisingly not versus capecitabine alone. However, the authors pointed out that there were some limits to the study, such as censored data and baseline imbalance in Kaplan Meyer curves, that could have inferred on the evaluation of the capecitabine arm\[[@B19]\]. Thus, the combination of everolimus + exemestane was confirmed to benefit these patients, whereas the superiority/equivalence/inferiority of capecitabine needs further clinical evaluation.

Inhibition of PI3K has been also investigated as an alternative strategy in targeted therapies of the mTOR pathway. As an example, buparlisib (BKM120), which is a PI3K inhibitor, has been tested in combination with fulvestrant in patients progressing AIs (BELLE-2, NCT01610284) and in patients progressing mTOR inhibition (BELLE-3, NCT01633060).

Buparlisib has been tested in 1147 patients as second line in the randomized, double-blinded BELLE-2 clinical trial, alone or in combination with fulvestrant. It was clear that the combination with the PI3K inhibitor had slightly increased PFS compared to fulvestrant alone, with the exception of *PI3KCA* mutated patients who improved the PFS of about 4 mo. Of note, the serious toxicity of buparsilib limited the efficacy of the targeted therapy\[[@B20]\]. BELLE-3 was a randomized double-blinded phase 2 trial enrolling 432 patients who progressed AIs to evaluate PFS in buparlisib + fulvestrant arm compared to fulvestrant + placebo. The combination with buparlisib improved the PFS of only 2 mo while showing a high toxicity profile that hampered the clinical benefit\[[@B21]\]. Finally, an exploratory strategy is aiming for the simultaneous inhibition of PI3K and mTOR by alpelisib (BYL719) and everolimus, respectively. The safety of the combination of alpelisib and everolimus alone or everolimus + exemestane has been tested in a Phase 1 trial in various solid tumours, including BC (NCT02077933).

Worth of note is the combination of letrozole and alpelisib, a selective oral inhibitor of the class I PI3K catalytic subunit p110α, which has shown synergistic antitumour activity with endocrine therapy against ER+/*PIK3CA*-mutated BC cells. The combination was safe with reversible toxicities. Clinical activity was observed independently of *PIK3CA* mutation status, although clinical benefit was seen in a higher proportion of patients with *PIK3CA*-mutated tumours. Phase 2 and 3 trials of alpelisib and endocrine therapy in patients with ER^+^ BC are ongoing\[[@B22]\].

PERSPECTIVE
===========

In addition to the previous therapies targeting mTOR, other research groups sought to investigate alternative strategies targeting molecules belonging to the mTOR complex or other effectors of the PI3K-mTOR pathway. An investigatory strategy consists in the use of sapanisertib (TAK228) for TORC1/2 inhibition by targeting mTOR kinase. TORC1/2 are complexes of proteins that regulate many vital cellular processes and proliferation. This drug has been tested in the neoadjuvant setting with tamoxifen (NCT02988986) or letrozole (NCT02619669) in the treatment of HR+ BC patients. AZD5363 is a specific Akt inhibitor, which has been tested either as a monotherapy (NCT01226316) or as a combination with fulvestrant in HR+ MBC patients who progressed AIs (NCT01992952). Table [1](#T1){ref-type="table"} summarizes all the clinical trials testing PI3K-mTOR pathway inhibitors. In our opinion, there is a need for predictors of the efficacy of such inhibitors: a pooled analysis for overall survival, disease free survival and PFS meta-analysis using clinical studies investigating the prognostic role of *PI3KCA* mutations in BC, proved that mutations of this gene are predictive of a worse clinical survival outcome for the patients (HR = 1.67, 95%CI: 1.15-2.43; *P* = 0.007)\[[@B23]\]. Unfortunately, there was not enough clinical evidence to prove that *PI3KCA* mutations could be predictive for therapy-efficacy and further clinical trials investigating the role of such mutations could be precious for guiding clinicians to choose those patients who would benefit from PI3K-mTOR inhibition treatment.

###### 

Clinical trials inhibiting PI3K-mTOR pathway in HR+, HER2- breast cancer patients

  **Clinical trial identifier**      **Phase**   **Year**     **Administered drug(s) (target)**                                                                                                                                                                                           **Primary endpoint**                            **Target/s of the PI3K-mTOR pathway**
  ---------------------------------- ----------- ------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ---------------------------------------
  NCT00699491                        1/2         18.06.2008   Cixutumumab + temsirolimus                                                                                                                                                                                                  ORR                                             mTOR
  Bolero 2; NCT00863655 \[[@B16]\]   3           18.03.2009   Everolimus + exemestane or placebo + exemestane                                                                                                                                                                             PFS                                             mTOR
  NCT00876395                        3           06.04.2009   Everolimus + placebo                                                                                                                                                                                                        PFS                                             mTOR
  NCT01219699                        1           13.10.2010   BYL719 + fulvestrant                                                                                                                                                                                                        MTD                                             PI3Kα
  NCT01283789                        2           26.01.2011   Everolimus + lapatinib                                                                                                                                                                                                      ORR                                             mTOR
  TAMRAD; NCT01298713 \[[@B14]\]     2           18.02.2011   Everolimus + tamoxifen                                                                                                                                                                                                      CBR                                             mTOR
  BELLE-2; NCT01610284               3           04.06.2012   Fulvestrant ± BKM120 (AIs refractory pts)                                                                                                                                                                                   PFS                                             PI3K
  BELLE-3; NCT01633060               3           04.06.2012   Fulvestrant ± BKM120 (Pts previously on mTOR inhibitors)                                                                                                                                                                    PFS                                             PI3K
  NCT01627067                        2           25.06.2012   Everolimus + exemestane + metformin                                                                                                                                                                                         PFS                                             mTOR
  NCT01674140                        3           28.08.2012   Everolimus + standard adjuvant endocrine therapy (tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or exemestane)                                                                          Invasive DFS                                    mTOR
  Bolero 4; NCT01698918              2           03.10.2012   Everolimus + letrozole                                                                                                                                                                                                      PFS                                             mTOR
  NCT01776008                        2           25.01.2013   everolimus + exemestane; MK2206 + anastrozole ± goserelin acetate                                                                                                                                                           CRR                                             Akt
  NCT01783444; Bolero-6              2           05.02.2013   Everolimus or capecitabine or everolimus + exemestane                                                                                                                                                                       PFS                                             mTOR
  NCT01791478                        1           15.02.2013   BYL719 + letrozole                                                                                                                                                                                                          DLT                                             PI3Kα
  NCT01805271                        3           06.03.2013   Everolimus + placebo                                                                                                                                                                                                        DFS                                             mTOR
  CLEE011X2107; NCT01872260          1b/2        07.06.2013   Letrozole + ribociclib + alpesilib                                                                                                                                                                                          DLT                                             PI3K
  INPRES; NCT01948960                4           24.09.2013   Everolimus                                                                                                                                                                                                                  AUC correlation with age and/or obesity         mTOR
  NCT01992952                        1/2         25.11.2013   Fulvestrant ± AZD5363 or placebo                                                                                                                                                                                            MTD                                             Akt
  PEARL; NCT02028364                 2           07.01.2014   Everolimus + exemestane                                                                                                                                                                                                     PFS and response by PET                         mTOR
  NCT02035813                        2           14.01.2014   Everolimus + eribulin                                                                                                                                                                                                       PFS                                             mTOR
  NCT02049957                        1b/2        30.01.2014   MLN0128 + exemestane *vs* MLN0128 + fulvestrant                                                                                                                                                                             Participant with AE and Clinical Benefit Rate   mTORC1/2
  NCT02057133                        1b          06.02.2014   LY2835219 + exemestane + everolimus *vs* exemestane + everolimus *vs* LY2835219 + trastuzumab *vs* LY2835219 + anastrazole *vs* LY2835219 + tamoxifen *vs* LY2835219 + letrozole *vs* LY3023414 + LY2835219 + fulvestrant   Safety                                          mTOR
  NCT02058381                        1b          10.02.2014   BYL719 + BKM120                                                                                                                                                                                                             MTD                                             PI3Kα + PI3K
  NCT02077933                        1           04.03.2014   Alpelisib + everolimus + exemestane                                                                                                                                                                                         DLT and MTD                                     PI3K + mTOR
  NCT02123823                        1b          28.04.2014   BI 836845 + everolimus + exemestane                                                                                                                                                                                         PFS, MTD and DLT                                mTOR
  NCT02216786                        2           15.08.2014   Everolimus + fulvestrant *vs* AZD2014 + fulvestrant                                                                                                                                                                         PFS                                             mTOR + mTORC1/2
  NCT02236572                        2           10.09.2014   Everolimus + aromatase inhibitor                                                                                                                                                                                            Preoperative Endocrine Prognostic Index         mTOR
  NCT02269670                        2           21.10.2014   Everolimus + endocrine therapy (anastrozole, letrozole, tamoxifen citrate, fulvestrant or megestrol acetate)                                                                                                                PFS and ORR                                     mTOR
  NCT02285179                        1/2         16.11.2014   Taselisib + tamoxifen                                                                                                                                                                                                       MTD                                             PI3K
  NCT02291913                        2           17.11.2014   Everolimus + anti-estrogen therapy (exemestane, tamoxifen, fulvestrant, anastrozole, letrozole, toremifine )                                                                                                                PFS                                             mTOR
  Sandpiper NCT02340221              3           16.01.2015   Taselisib + fulvestrant *vs* placebo + fulvestrant                                                                                                                                                                          PFS                                             PI3K
  FEVEX; NCT02404051                 3           31.03.2015   Everolimus + exemestane *vs* everolimus + exemestane (at progression fulvestrant)                                                                                                                                           PFS                                             mTOR
  NCT02404844                        2           01.04.2015   BKM120 + tamoxifen                                                                                                                                                                                                          PFS                                             PI3K
  NCT02379247                                    04.05.2015   BYL719 + Nab-paclitaxel                                                                                                                                                                                                     DLT , ORR for Phase II                          PI3Kα
  SOLAR-1; NCT02437318               3           07.05.2015   Fulvestrant ± alpelisib (AIs refractory pts)                                                                                                                                                                                PFS                                             PI3K
  NCT02506556                        2           23.07.2015   BYl719                                                                                                                                                                                                                      ORR                                             PI3Kα
  NCT02511639                        3           30.07.2015   Everolimus + aromatase inhibitors                                                                                                                                                                                           PFS                                             mTOR
  NCT02520063                        1/2         11.08.2015   Letrozole + everolimus + TRC105                                                                                                                                                                                             MTD                                             mTOR
  NCT02619669                        1           02.12.2015   Sapanisertib + letrozole                                                                                                                                                                                                    TAE                                             mTORC1/2
  TRINITI-1; NCT02732119             1/2         08.04.2016   Everolimus + ribociclib + exemestane                                                                                                                                                                                        MTD                                             mTOR
  NCT02742051                        2           18.04.2016   Everolimus + letrozole *vs* neoadjuvant+ fluorouracil, epirubicin + cyclophosphamide (FEC)                                                                                                                                  ORR                                             mTOR
  NCT02871791                        2           18.08.2016   Everolimus + exemestane                                                                                                                                                                                                     DLT                                             mTOR
  NCT02988986                        2           12.12.2016   Sapanisertib + tamoxifen                                                                                                                                                                                                    Change in Ki67 expression                       mTORC1/2
  CLEVER; NCT03032406                2           26.01.2017   Everolimus ± hydroxychloroquine                                                                                                                                                                                             AE                                              mTOR
  NCT03056755                        2           17.02.2017   Alpelisib + fulvestrant + letrozole (AIs and CDK4/6 refractory pts)                                                                                                                                                         DFS                                             PI3K
  NCT03128619                        1/2         25.04.2017   Copanlisib + letrozole + palbociclib                                                                                                                                                                                        MTD                                             PI3K
  EVEREXES; NCT03176238              3           05.06.2017   Everolimus + exemestane                                                                                                                                                                                                     AE                                              mTOR
  NCT03207529                        1           02.07.2017   BYL719 + enzalutamide                                                                                                                                                                                                       MTD                                             PI3Kα
  NCT03377101                        2           19.12.2017   Fulvestrant + palbociclib ± copanlisib                                                                                                                                                                                      DLT                                             PI3K

DLT: Dose limiting toxicity; PFS: Progression free survival; DFS: Disease free survival; MTD: Maximum tolerated dose; AE: Adverse events; CBR: Clinical benefit rate; ORR: Overall response rate; CRR: Clinical response rate; PI3K-mTOR: Phosphatidylinositol 3-kinase-mammalian target of rapamycin.

In conclusion, the inhibition of the PI3K-mTOR pathway remains one of the major goals for the treatment of HR+ advanced BC patients. It is known that targeting more upstream effectors, such as PI3K, which proved to be very promising based on *in vitro* evidence, lead to major side effects in clinical studies, limiting the clinical development of this type of drugs. This class of inhibitors, however, seems to be beneficial for patients harboring *PI3KCA* mutations, thus producing less toxicity.

Currently, everolimus remains the best option in the clinical setting in combinational therapies for HR+ BC patients. Moreover, several studies are directed to explore the clinical benefits of everolimus in combination with other drugs, as illustrated in Table [1](#T1){ref-type="table"}. Of note, 10%-15% of patients are intrinsically resistant to everolimus treatment\[[@B24]\]. For this reason, dual inhibition of the pathway by targeting mTORC1/2 proteins have been tested (Table [1](#T1){ref-type="table"}), and some phase 1 studies are exploring new PI3K inhibitors, such as gedatolisib (NCT02626507) in neoadjuvant setting for ER+, HER2- BC patients. CUDC-907, an histone deacetylase and PI3K inhibitor (NCT02307240), and AZD8186, a PI3K-β inhibitor (NCT03218826), have been tested in advanced solid tumours, including BC. Having biomarkers from the metastatic setting to predict the responsiveness/resistance to anti-PI3K/mTOR/Akt drugs are thus an urgent task, and many efforts in this direction are expected. Finally, with the advancement of immune-therapy, trials testing the combination of immune-therapy with everolimus are warranted.
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